Blood test dynamics in hospitalized COVID-19 patients : Potential utility of D-dimer for pulmonary embolism diagnosis
BACKGROUND: A higher incidence of thrombotic events, mainly pulmonary embolism (PE), has been reported in hospitalized patients with COVID-19. The main objective was to assess clinical and laboratory differences in hospitalized COVID-19 patients according to occurrence of PE.
METHODS: This retrospective study included all consecutive patients hospitalized with COVID-19 who underwent a computed tomography (CT) angiography for PE clinical suspicion. Clinical data and median blood test results distributed into weekly periods from COVID-19 symptoms onset, were compared between PE and non-PE patients.
RESULTS: Ninety-two patients were included, 29 (32%) had PE. PE patients were younger (63.9 (SD 13.7) vs 69.9 (SD 12.5) years). Clinical symptoms and COVID-19 CT features were similar in both groups. PE was diagnosed after a mean of 20.0 (SD 8.6) days from the onset of COVID-19 symptoms. Corticosteroid boluses were more frequently used in PE patients (62% vs. 43%). No patients met ISTH DIC criteria. Any parameter was statistically significant or clinically relevant except for D-Dimer when comparing both groups. Median values [IQR] of D-dimer in PE vs non-PE patients were: week 2 (2010.7 [770.1-11208.9] vs 626.0 [374.0-2382.2]; p = 0.004); week 3 (3893.1 [1388.2-6694.0] vs 1184.4 [461.8-2447.8]; p = 0.003); and week 4 (2736.3 [1202.1-8514.1] vs 1129.1 [542.5-2834.6]; p = 0.01). Median fold-increase of D-dimer between week 1 and 2 differed between groups (6.64 [3.02-23.05] vs 1.57 [0.64-2.71], p = 0.003); ROC curve AUC was 0.879 (p = 0.003) with a sensitivity and specificity for PE of 86% and 80%, respectively.
CONCLUSIONS: Among hospitalized COVID-19 patients, D-dimer levels are higher at weeks 2, 3 and 4 after COVID-19 symptom onset in patients who develop PE. This difference is more pronounced when the fold increase between weeks 1 and 2 is compared.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
---|---|
Enthalten in: |
PloS one - 15(2020), 12 vom: 28., Seite e0243533 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Cerdà, Pau [VerfasserIn] |
---|
Links: |
---|
Themen: |
Fibrin Fibrinogen Degradation Products |
---|
Anmerkungen: |
Date Completed 11.01.2021 Date Revised 11.01.2021 published: Electronic-eCollection Citation Status MEDLINE |
---|
doi: |
10.1371/journal.pone.0243533 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM319345181 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM319345181 | ||
003 | DE-627 | ||
005 | 20231225171242.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1371/journal.pone.0243533 |2 doi | |
028 | 5 | 2 | |a pubmed24n1064.xml |
035 | |a (DE-627)NLM319345181 | ||
035 | |a (NLM)33370304 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Cerdà, Pau |e verfasserin |4 aut | |
245 | 1 | 0 | |a Blood test dynamics in hospitalized COVID-19 patients |b Potential utility of D-dimer for pulmonary embolism diagnosis |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.01.2021 | ||
500 | |a Date Revised 11.01.2021 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: A higher incidence of thrombotic events, mainly pulmonary embolism (PE), has been reported in hospitalized patients with COVID-19. The main objective was to assess clinical and laboratory differences in hospitalized COVID-19 patients according to occurrence of PE | ||
520 | |a METHODS: This retrospective study included all consecutive patients hospitalized with COVID-19 who underwent a computed tomography (CT) angiography for PE clinical suspicion. Clinical data and median blood test results distributed into weekly periods from COVID-19 symptoms onset, were compared between PE and non-PE patients | ||
520 | |a RESULTS: Ninety-two patients were included, 29 (32%) had PE. PE patients were younger (63.9 (SD 13.7) vs 69.9 (SD 12.5) years). Clinical symptoms and COVID-19 CT features were similar in both groups. PE was diagnosed after a mean of 20.0 (SD 8.6) days from the onset of COVID-19 symptoms. Corticosteroid boluses were more frequently used in PE patients (62% vs. 43%). No patients met ISTH DIC criteria. Any parameter was statistically significant or clinically relevant except for D-Dimer when comparing both groups. Median values [IQR] of D-dimer in PE vs non-PE patients were: week 2 (2010.7 [770.1-11208.9] vs 626.0 [374.0-2382.2]; p = 0.004); week 3 (3893.1 [1388.2-6694.0] vs 1184.4 [461.8-2447.8]; p = 0.003); and week 4 (2736.3 [1202.1-8514.1] vs 1129.1 [542.5-2834.6]; p = 0.01). Median fold-increase of D-dimer between week 1 and 2 differed between groups (6.64 [3.02-23.05] vs 1.57 [0.64-2.71], p = 0.003); ROC curve AUC was 0.879 (p = 0.003) with a sensitivity and specificity for PE of 86% and 80%, respectively | ||
520 | |a CONCLUSIONS: Among hospitalized COVID-19 patients, D-dimer levels are higher at weeks 2, 3 and 4 after COVID-19 symptom onset in patients who develop PE. This difference is more pronounced when the fold increase between weeks 1 and 2 is compared | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Fibrin Fibrinogen Degradation Products |2 NLM | |
650 | 7 | |a fibrin fragment D |2 NLM | |
700 | 1 | |a Ribas, Jesus |e verfasserin |4 aut | |
700 | 1 | |a Iriarte, Adriana |e verfasserin |4 aut | |
700 | 1 | |a Mora-Luján, José María |e verfasserin |4 aut | |
700 | 1 | |a Torres, Raquel |e verfasserin |4 aut | |
700 | 1 | |a Del Río, Belén |e verfasserin |4 aut | |
700 | 1 | |a Jofre, Héctor Ignacio |e verfasserin |4 aut | |
700 | 1 | |a Ruiz, Yolanda |e verfasserin |4 aut | |
700 | 1 | |a Huguet, Marta |e verfasserin |4 aut | |
700 | 1 | |a Fuset, Mari Paz |e verfasserin |4 aut | |
700 | 1 | |a Martínez-Yélamos, Sergio |e verfasserin |4 aut | |
700 | 1 | |a Santos, Salud |e verfasserin |4 aut | |
700 | 1 | |a Llecha, Núria |e verfasserin |4 aut | |
700 | 1 | |a Corbella, Xavier |e verfasserin |4 aut | |
700 | 1 | |a Riera-Mestre, Antoni |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t PloS one |d 2006 |g 15(2020), 12 vom: 28., Seite e0243533 |w (DE-627)NLM167327399 |x 1932-6203 |7 nnns |
773 | 1 | 8 | |g volume:15 |g year:2020 |g number:12 |g day:28 |g pages:e0243533 |
856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0243533 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 15 |j 2020 |e 12 |b 28 |h e0243533 |